PKI earnings

Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

PerkinElmer Inc. (NYSE:PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 –

Fourth quarter revenue from continuing operations of $741 million; (28)% reported growth; (23)% organic growth; 8% non-COVID organic growth Combined* total fourth quarter revenue of $1,089 million; 8% combined non-COVID organic growth Fourth quarter GAAP EPS from continuing operations of $0.85; combined adjusted EPS of $1.70 Initiates Full Year 2023 Guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 1, 2023. Fourth Quarter 2022 The Company reported GAAP earnings per share from continuing operations of $0.85, as compared to GAAP earnings per share

PerkinElmer Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2022 financial results prior to market open on Tuesday, February 14, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. The Company is also updating its fourth quarter 2022 guidance as previously provided on Novembe

Third quarter revenue of $712 million; (17)% reported growth Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth Third quarter GAAP EPS from continuing operations of $0.55; pro forma adjusted EPS of $1.51 Initiates fourth quarter and updates full year pro forma guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 2, 2022. The Company reported GAAP earnings per share from continuing operations of $0.55, as compared to GAAP earnings per share from continuing operations of $0.94 in the same period a year ago. GAAP revenue for the quarter

Signs agreement with the intention to divest Applied, Food, and Enterprise Services businesses Second quarter revenue of $1.23 billion; 0% reported growth, 8% non-COVID organic growth Second quarter GAAP EPS from continuing operations of $1.42; adjusted EPS of $2.32 Initiates third quarter and raises full year guidance Earnings call moved to today at 8:00 a.m. Eastern Time. Webcast information below PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 3, 2022. The Company reported GAAP earnings per share from continuing operations of $1.42, as compared to GAAP earnings per s

PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022 at 6:00 a.m. ET. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. A replay of the webcast will be available beginning at 10:00 a.m. ET, Thursday, Augu

First quarter revenue of $1.26 billion First quarter GAAP EPS from continuing operations of $1.40; Adjusted EPS of $2.41 Initiates Second Quarter and Raises Full Year Guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 3, 2022. The Company reported GAAP earnings per share from continuing operations of $1.40, as compared to GAAP earnings per share from continuing operations of $3.37 in the same period a year ago. GAAP revenue for the quarter was $1.26 billion, as compared to $1.31 billion in the same period a year ago. GAAP operating income from continuing operations f

PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the Company will release its first quarter 2022 financial results after market close on Tuesday, May 3, 2022. The Company will host a conference call the same day at 5:00 p.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. A replay of the webcast will be available beginning at 7:00 p.m. ET, Tuesday, May 3, 2

4Q Revenue of $1.36 billion; 1% reported growth; -9% organic growth 4Q GAAP EPS from continuing operations of $1.41; Adjusted EPS of $2.56 Initiates First Quarter and Full Year 2022 Guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 2, 2022. Fourth Quarter 2021 The Company reported GAAP earnings per share from continuing operations of $1.41, as compared to GAAP earnings per share from continuing operations of $3.38 in the fourth quarter of 2020. GAAP revenue for the quarter was $1.36 billion, as compared to $1.35 billion in the fourth quarter of 202

Fourth quarter 2021 revenue and earnings per share to exceed prior guidance Non-COVID organic growth in fourth quarter 2021 of approximately 10% Fourth quarter 2021 COVID product and services related revenue of approximately $320 million PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth for the fourth quarter of 2021 of approximately -1% and -12%, respectively, versus the same period a year ago. Adjusted earnings per share from continuing operations is expected to be at least $2.40 for the fourth quarter ended January 2, 2022. The stronger than expected results in the f

Revenue of $1.17 billion; 21% reported growth; 12% organic growth GAAP EPS from continuing operations of $1.11; Adjusted EPS of $2.31 Initiates Fourth Quarter Guidance and Raises Full Year Revenue and Earnings Guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 3, 2021. The Company reported GAAP earnings per share from continuing operations of $1.11, as compared to GAAP earnings per share from continuing operations of $1.57 in the third quarter of 2020. GAAP revenue for the quarter was $1.17 billion, as compared to $964 million in the third quarter of 2020. GAAP ope

PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the Company will release its third quarter 2021 financial results after market close on Tuesday, November 2, 2021. The Company will host a conference call the same day at 5:00 p.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call. To access the call, a live audio webcast of the call will be available via this registration form or on the Investors section of the Company's website at www.perkinelmer.com. A replay of the webcast will be available begi

Revenue of $1.228 billion; 51% reported growth; 41% organic growth GAAP EPS from continuing operations of $2.19; Adjusted EPS of $2.83 Initiates Third Quarter and Raises Full-Year Revenue and Earnings Guidance Announces Agreement to Acquire BioLegend – Leading Antibody & Research Reagent Provider Earnings Call Moved to Today at 8:00 a.m. Eastern Time; Dial-in Information Below PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 4, 2021. The Company reported GAAP earnings per share from continuing operations of $2.19, as compared to GAAP earnings per share from continuing op

Transformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine Leader in antibody development with highly complementary, innovative portfolio in emerging, high-growth areas of biologics, cell and gene therapy, proteogenomics, and recombinant proteins Commercial synergy opportunity to accelerate life science growth with potential benefits for diagnostics franchise Annual BioLegend revenues of approximately $380 million estimated in 2022 with mid-teens-plus expected revenue growth (excluding synergies) Elevated growth and margin profile for combined company with strong, immediate adjusted earnings per share accreti

Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings Guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 4, 2021. The Company reported GAAP earnings per share from continuing operations of $3.37, as compared to GAAP earnings per share from continuing operations of $0.30 in the first quarter of 2020. GAAP revenue for the quarter was $1.308 billion, as compared to $652 million in the first quarter of 2020. GAAP operating i

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 3, 2021. Fourth Quarter 2020 The Company reported GAAP earnings per share from continuing operations of $3.38, as compared to GAAP earnings per share from continuing operations of $0.58 in the fourth quarter of 2019. GAAP revenue for the quarter was $1.355 billion, as compared to $805 million in the fourth quarter of 2019. GAAP operating income from continuing operations for the quarter was $510 million, as compared to $138 million for the same period a year ago. GAAP ope